Browse drugs

…se aged 16-39. Cancer yield in FIT<10 was 0.3% (95% CI 0.2–0.3).FIT concentration was strongly associated with cancer; aOR 46.1 (95…

…DM were enrolled in iDiabetesPlus and 349(97.2%) had successful FIB4 calculation. A higher proportion of individuals in the intermed…

…nce in pregnancy. Seizure risk was better explained by baseline lamotrigine dose.…

… therapies produce substantial reductions in Lp(a) levels, with Olpasiran demonstrating the greatest efficacy. Overall, these agents exhi…

…ceramide (GB3), causing progressive, multisystem tissue damage. Migalastat is an oral chaperone therapy that stabilises defective enzyme i…

…T-GSK-3β/β-catenin axis.Conclusion This study demonstrates that 4’-O-Methylochnaflavone promotes myocardial regeneration by directly targeting AKT to o…

…firmed in 31 patients (PPV 62%), including 20 with HFrEF. Using NT-proBNP alone, efficiency was limited: 1.61 TTEs per confirmed HF and 2…

…y cells, in both single-agent and in combination treatment with atezolizumab. This was accompanied by transient elevation of granulocyte-mac…

…ivation profile relying on the activation of JAK/STAT pathways. Tofacitinib, a pan-JAK inhibitor, down regulates interferon (IFN) in human …

…ivo model using human lung biopsies showed that incubation with ATA also caused a marked increase in IFNb and CXCL10 synthesisConcl…

…e during follow-up.Conclusions In this large real-world cohort, CAB+RPV showed durable effectiveness and good tolerability through 144 …

…essment for insulin resistance (HOMA-IR) among PWH treated with rosuvastatin vs. atorvastatin. The secondary objectives were to evaluate bas…